STOK STOKE THERAPEUTICS INC
FollowCOM (common), issuer CIK 1623526
Filings received so far for Q3 2026: 3 13F filers report a position in STOK shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.
- BIOTECHNOLOGY VALUE FUND L P(group BVF INC/IL)
3,608,968 shares, 5.6% in a 13G as of 2026-09-23,0000921895-26-002685
Accepted , ingested
Insider trades
No Form 4 transaction on this security in the data.
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
| Holder | Shares | Value | % of portfolio | Change | Source |
|---|---|---|---|---|---|
| Versant Capital Management, Inc | 1,773 | $46.1K | <0.01% | -178 | 13F-HRTimeline |
| GAMMA Investing LLC | 1,047 | $27.2K | <0.01% | +164 | 13F-HRTimeline |
| Farther Finance Advisors, LLC | 17 | $442 | <0.01% | 0 | 13F-HRTimeline |
Events
BIOTECHNOLOGY VALUE FUND L P and 9 other reporting persons reported 3,608,968 STOK shares, 5.6% of the class, as of 2026-09-23, in a 13G filed 2026-09-30. 0000921895-26-002685
Accepted , ingested